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Abstract
Background: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with 
type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well 
tolerated compared with treatment with control agents. As clinical development of sitagliptin continues, additional 
studies have been completed, and more patients have been exposed to sitagliptin. The purpose of the present analysis 
is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies.
Methods: The present analysis included data from 10,246 patients with type 2 diabetes who received either sitagliptin 
100 mg/day (N = 5,429; sitagliptin group) or a comparator agent (placebo or an active comparator) (N = 4,817; non-
exposed group). The 19 studies from which this pooled population was drawn represent the double-blind, randomized 
studies that included patients treated with the usual clinical dose of sitagliptin (100 mg/day) for between 12 weeks and 
2 years and for which results were available as of July 2009. These 19 studies assessed sitagliptin taken as monotherapy, 
initial combination therapy with metformin or pioglitazone, or as add-on combination therapy with other 
antihyperglycemic agents (metformin, pioglitazone, a sulfonylurea ± metformin, insulin ± metformin, or rosiglitazone + 
metformin). Patients in the non-exposed group were taking placebo, metformin, pioglitazone, a sulfonylurea ± 
metformin, insulin ± metformin, or rosiglitazone + metformin. The analysis used patient-level data from each study to 
evaluate between-group differences in the exposure-adjusted incidence rates of adverse events.
Results: Summary measures of overall adverse events were similar in the sitagliptin and non-exposed groups, except 
for an increased incidence of drug-related adverse events in the non-exposed group. Incidence rates of specific 
adverse events were also generally similar between the two groups, except for increased incidence rates of 
hypoglycemia, related to the greater use of a sulfonylurea, and diarrhea, related to the greater use of metformin, in the 
non-exposed group and constipation in the sitagliptin group. Treatment with sitagliptin was not associated with an 
increased risk of major adverse cardiovascular events.
Conclusions: In this updated pooled safety analysis of data from 10,246 patients with type 2 diabetes, sitagliptin 100 
mg/day was generally well tolerated in clinical trials of up to 2 years in duration.
Background
The safety and tolerability of sitagliptin, a dipeptidyl pep-
tidase-4 (DPP-4) inhibitor, were found to be generally
comparable to non-sitagliptin treatments in a pooled
analysis of 12 double-blind, randomized, controlled stud-
ies comprising data on 6,139 patients with type 2 diabetes
that was published in 2008 [1]. Concurrent with the
increased use of sitagliptin (administered as either sita-
gliptin tablets or as sitagliptin/metformin fixed-dose
combination tablets) in clinical practice, additional clini-
cal studies have expanded the controlled trial dataset that
informs the safety experience with sitagliptin. In this
updated report, the safety and tolerability of sitagliptin
100 mg/day were examined in a pooled analysis of
patient-level data from 19 double-blind, randomized
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studies that included 10,246 patients with type 2 diabetes.
Endpoints of particular interest regarding the safety of
medications used in patients with type 2 diabetes (e.g.,
cardiovascular adverse events [2] and adverse events of
malignancy [3]) were evaluated in greater detail, as were
adverse events potentially related to the mechanism of
action of specific antihyperglycemic agents (AHAs) (e.g.,
hypoglycemia, gastrointestinal intolerance, bone frac-
tures [4-7]), and events postulated to be potentially
related to inhibition of the DPP-4 enzyme [8-10].
Methods
Similar to the previous report that assessed pooled,
patient-level data [1], the present analysis evaluated the
usual clinical dose of sitagliptin (100 mg/day) approved
for use in patients with type 2 diabetes. The pooled popu-
lation was drawn from all 19 multicenter, U.S. or multina-
tional, double-blind, parallel-group studies conducted by
Merck Sharp & Dohme Corp., in which patients were
randomized to receive sitagliptin 100 mg/day (or compar-
ator) for at least 12 weeks and up to 2 years (the duration
of the longest studies) and for which results were avail-
able as of July 2009. Protocols were reviewed and
approved by appropriate ethical review committees and
authorities for each clinical site; all patients were to have
provided written informed consent. These studies
assessed sitagliptin when used as monotherapy, initial
combination therapy with either metformin or pioglita-
zone, or add-on combination therapy with other AHAs
including metformin, pioglitazone, a sulfonylurea (with
and without metformin), insulin (with and without met-
formin), or metformin + rosiglitazone. Patients not
receiving sitagliptin (i.e., the non-exposed group)
received placebo, metformin, pioglitazone, a sulfonylu-
rea, (with and without metformin), insulin (with and
without metformin), or metformin + rosiglitazone. From
each contributing study, the pooling was conducted by
including portions of controlled, double-blind studies
that had parallel treatment groups with concurrent expo-
sures to sitagliptin 100 mg/day (primarily administered as
100 mg once daily) or other treatments (either placebo or
active-comparator; see Table 1 for a listing of studies).
Sitagliptin 100 mg/day was administered as 50 mg twice
daily, either alone or in combination with metformin, in 4
studies: two dose-range finding studies [11,12], the study
of initial combination therapy with sitagliptin and met-
formin that simulated the twice-daily administration of a
fixed-dose combination of sitagliptin and metformin [13],
and the study in which the fixed-dose combination tablet
of sitagliptin and metformin was administered twice daily
[14,15]. Studies conducted only in Japan were excluded
from all analyses; a lower starting dose of sitagliptin has
been separately developed in Japan. Similarly, the pooling
did not include results from patients with renal insuffi-
ciency randomized to receive dose-adjusted sitagliptin at
less than 100 mg/day, including results from a special
populations study of patients with moderate or severe/
end-stage renal insufficiency who were randomized to
receive either 50 or 25 mg once daily [16].
Baseline demographics and disease characteristics were
summarized for the pooled population and for each treat-
ment group. For race/ethnicity, the data capture system
was changed (2008) to reflect the US FDA guidance [17]
regarding the collection of race and ethnicity data in clin-
ical trials (i.e., categorization of Hispanic/Latino back-
ground as ethnicity, independent of race). Consequently,
data reflecting Hispanic/Latino background were not col-
lected in a consistent manner across all studies, and can-
not be pooled and summarized.
In each study included in this pooled analysis, investi-
gators were to report adverse events (serious and non-
serious) that occurred during the conduct of the study.
Further, all serious adverse events occurring within 14
days following the last dose of blinded study drug were to
have been reported. This pooled analysis used patient -
level data from each study to assess the incidence rates of
specific adverse events that occurred following initiation
of double-blind study drug. These events were encoded
in a uniform manner using the Medical Dictionary for
Regulatory Activities (MedDRA version 12.0), in which
terms for specific adverse events that are alike or pertain
to the same organ system are categorized by System
Organ Class (SOC). To account for potential differences
between groups in duration of exposure to treatment,
reports of adverse events are expressed as exposure-
adjusted incidence rates (numbers of patients with events
per 100 patient-years). These analyses were based upon
the time to the first (incident) event, calculated as fol-
lows: incident event rate = 100 * (total number of patients
with ≥ 1 event during eligible exposure period per total
patient-years of exposure). The incident event rate per
100 patient-years is referred to as the "incidence rate"
throughout the manuscript. For patients for whom an
event was reported, the patient-years of exposure were
calculated as the time from the first dose of sitagliptin (or
comparator) at randomization to the time that the first
post-randomization event occurred. For patients without
an event, the patient-years of exposure were calculated as
the time from the first dose to 14 days after the last dose
of study medication (i.e., sitagliptin or comparator).
Most of the studies in this analysis included open-label
glycemic rescue therapy. Glycemic rescue therapies
included metformin, a thiazolidinedione, a sulfonylurea,
or an insulin dose increase (in the add-on to insulin
study), and were to have been initiated based upon pro-
gressively stricter, protocol-specified hyperglycemic cri-
teria. When initiated, glycemic rescue therapy was added
to the ongoing, blinded study medication to whichWilliams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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Table 1: Studies and treatment arms included in the primary analysis
Study Study Design Sitagliptin 100 mg 
Group
(N = 5429)
n Non-exposed
Group
(N = 4817)
n Reference*
P010: twice-daily
dose-range 
finding
study
106-week active-
controlled
period
Sitagliptin 50 mg b.i.d.
switched to Sitagliptin 
100 mg q.d.
122 Glipizide 123 [11]
P014: once-daily
dose-range 
finding study
12-week placebo-
controlled
period and 94-
week active-
controlled period
-Sitagliptin 100 mg q.d.
-Sitagliptin 50 mg b.i.d.
switched to Sitagliptin 
100 mg q.d.
110
111
Placebo (12 
weeks)
switched to 
metformin (94 
weeks)
111 [12]
P019: placebo-
controlled
add-on to 
pioglitazone 
study
24-week placebo-
controlled
period
Sitagliptin 100 mg q.d.
+ pioglitazone
175 Placebo
+ pioglitazone
178 [48]
P020: placebo-
controlled
add-on to 
metformin study
24-week placebo-
controlled
period and 80-
week active-
controlled period
Sitagliptin 100 mg q.d.
+ metformin
464 Placebo + 
metformin
(24 weeks) 
switched to 
glipizide + 
metformin
(80 weeks)
237 [49]
P021: placebo-
controlled 
monotherapy 
study
24-week placebo-
controlled
period
Sitagliptin 100 mg q.d. 238 Placebo 253 [50]
P023: placebo-
controlled 
monotherapy 
study
18-week placebo-
controlled
period and 36-
week active-
controlled period
Sitagliptin 100 mg q.d. 205 Placebo (18 
weeks)
switched to 
pioglitazone
(36 weeks)
110 [51]
P024: active-
comparator
controlled add-on 
to metformin 
study
104-week active-
controlled
period
Sitagliptin 100 mg q.d.
+ metformin
588 Glipizide
+ metformin
584 [23,24]
P035: placebo-
controlled
add-on to 
glimepiride, alone 
or in combination 
with metformin 
study
24-week placebo-
controlled
period and 30-
week active-
controlled period
Sitagliptin 100 mg q.d.
+ glimepiride (± 
metformin)
222 Placebo + 
glimepiride
(± metformin) (24 
weeks) switched 
to pioglitazone
+ glimepiride
(± metformin)
(30 weeks)
219 [25]
P036: placebo- 
and
active-controlled 
study of initial 
combination use 
of sitagliptin and 
metformin
24-week placebo-
controlled period; 
80-week active-
controlled period
-Sitagliptin 100 mg q.d.
-Sitagliptin 50 mg 
b.i.d./metformin 500 
mg b.i.d.
-Sitagliptin 50 mg 
b.i.d./metformin 1000 
mg b.i.d.
179
190
182
-Placebo (24 
weeks)
switched to
metformin (80
weeks)
-Metformin 500 
mg b.i.d.
-Metformin 1000 
mg b.i.d.
176
182
182
[13,52,53]Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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P040: placebo-
controlled 
monotherapy 
study
18-week placebo-
controlled period
Sitagliptin 100 mg q.d. 352 Placebo 178 [54]
P047: placebo-
controlled 
monotherapy 
study
in elderly patients
24-week placebo-
controlled
period
Sitagliptin 100 mg q.d 91 Placebo 92 [55]
P049: active-
comparator
controlled 
monotherapy
study
24-week active-
controlled
period
Sitagliptin 100 mg q.d 528 Metformin 522 [56]
P051: placebo-
controlled add-on 
to insulin, alone
or in combination 
with metformin 
study
24-week placebo-
controlled
period
Sitagliptin 100 mg q.d 
+ insulin (± metformin)
322 Placebo + insulin 
± metformin
319 [26]
P052: placebo-
controlled
add-on to 
metformin and 
rosiglitazone 
study
54-week placebo-
controlled
period
Sitagliptin 100 mg q.d. 
+ metformin and 
rosiglitazone
170 Placebo + 
metformin and 
rosiglitazone
92 [57]
P053: placebo-
controlled
add-on to 
metformin study
30-week placebo-
controlled
period
Sitagliptin 100 mg q.d. 
+ metformin
96 Placebo + 
metformin
94 [58]
P061: placebo- 
and
active-controlled 
mechanism
of action factorial 
study
12-week placebo-
controlled
period
-Sitagliptin 100 mg q.d.
-Sitagliptin 100 mg q.d. 
+ pioglitazone
52
52
-Pioglitazone
-Placebo
54
53
[28]
P064: active-
comparator
controlled study 
of initial 
combination use 
of sitagliptin and 
pioglitazone
54-week active-
controlled
period
Sitagliptin 100 mg q.d 
+ pioglitazone
261 Placebo + 
pioglitazone
259 [29]
P079: active-
comparator 
controlled study 
of initial 
combination use 
of sitagliptin/
metformin FDC 
(MK-0431A)
44-week active-
controlled period
Sitagliptin 50 mg + 
metformin 1000 mg 
b.i.d. (FDC)
625 Metformin 1000 
mg b.i.d.
621 [14,15]
P801: placebo- 
and
active-controlled 
add-on to 
metformin study
18-week placebo-
controlled period
Sitagliptin 100 mg q.d. 94 -Rosiglitazone
-Placebo
87
91
[59]
*References are for the initial phases of the studies that had extension or continuation phases, unless a reference is provided for the results 
beyond the initial phase.
q.d. = once daily; b.i.d. = twice daily
Table 1: Studies and treatment arms included in the primary analysis (Continued)Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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patients had been randomized. The primary analyses in
this pooled population present results of post-random-
ization events reported to have occurred during a given
study, including those events with onset after the initia-
tion of glycemic rescue therapy, unless otherwise speci-
fied. Results were summarized by SOC for specific
adverse events occurring with a reported incidence rate
of at least 1 incident event per 100 patient-years for either
the sitagliptin-exposed or the non-exposed group. Inci-
dence rates of specific adverse events reported with like
terms (e.g., "urinary tract infection", and "urinary tract
infection, bacterial") were pooled and assessed as sensi-
tivity analyses in some instances. Since drug-related and
serious clinical adverse events are a subset of all adverse
events and reported less frequently, these events were
summarized using a lower cut point (i.e., an incidence
rate of at least 0.2 incident events per 100 patient-years).
Differences between treatment groups and the associated
95% confidence intervals (CI) were calculated using the
Miettinen and Nurminen method, stratified by study
[18]. No statistical adjustments were performed for mul-
tiple comparisons. All analyses were performed using
SAS Version 9.1.
Although both analyses used patient-level data and
assessed all reported adverse events, there were some dif-
ferences in the methodologies used in the present analy-
sis relative to the previously published pooled analysis of
the safety of sitagliptin [1]. The primary approach in the
present analysis evaluated exposure-adjusted incidence
rates that included data after initiation of glycemic rescue
therapy. In contrast, the previous analysis examined
crude (i.e., not exposure-adjusted) incidence rates and
excluded data after initiation of glycemic rescue therapy.
In addition, the present analysis employed stratification
by study to account for potential differences among stud-
i e s  ( s u c h  a s  s a m p l e  s i z e  o r  r a n d o m i z a t i o n  r a t i o s ) .  T o
assess the robustness of the conclusions from the primary
analysis, the results were also analyzed after excluding
data following initiation of glycemic rescue therapy. In
addition, crude incidence rates were compared between
groups. Results from these analyses were generally con-
sistent with the primary analyses and are not presented
herein.
Adverse Events of Interest
For most studies, prespecified adverse events of interest
included hypoglycemia and predefined gastrointestinal
(GI) adverse events (including diarrhea, nausea, vomiting
and a composite abdominal pain term, which included
abdominal pain, upper and lower abdominal pain, and
abdominal and epigastric discomfort). For all of the trials
t h a t  w e r e  p o o l e d  f o r  t h i s  a n a l y s i s ,  h y p o g l y c e m i a  w a s
based upon investigator interpretation of clinical symp-
toms, without the requirement for a concurrent glucose
d e t e r m i n a t i o n .  I n  c o n t r a s t  t o  t h e  g e n e r a l  a n a l y s i s  o f
adverse events, analyses of hypoglycemia and predefined
GI adverse events excluded data following initiation of
glycemic rescue therapy to avoid the confounding influ-
ence of medications that could cause hypoglycemia or
gastrointestinal symptoms. In addition, a separate pooled
analysis was performed, using studies and portions of
studies that did not include a sulfonylurea or insulin, to
characterize the rate of hypoglycemia with sitagliptin rel-
ative to comparators not generally associated with an
increased risk for hypoglycemia (i.e., metformin and pio-
glitazone, as well as placebo). For the predefined GI
adverse events of interest, a separate pooled analysis was
conducted, excluding studies and portions of studies in
which patients initiated metformin, to characterize the
rate of these GI events with sitagliptin relative to compar-
ators generally not associated with an increased risk for
GI events. The analysis of reports of pancreatitis, an addi-
tional gastrointestinal adverse event of recent interest, is
presented elsewhere [19].
Cardiovascular
An analysis using major adverse cardiovascular events
(MACE) that focused on ischemic events (see Appendix I
for list of terms) and cardiovascular deaths was per-
formed to inform on the cardiovascular safety of sitaglip-
tin in patients with type 2 diabetes. There was no formal
adjudication of these cardiovascular adverse events.
Exposure-adjusted risk ratios were calculated using the
exact procedures for the Poisson processes [20]. A sensi-
tivity analysis was conducted using the Mantel-Haenszel
approach, a method which can accommodate studies
w i t h  n o  e v e n t s  [ 2 1 ] .  B o t h  a n a l y s e s  w e r e  s t r a t i f i e d  b y
study.
Malignancy
The Neoplasms SOC contains all adverse event terms for
malignancies, as well as terms for a variety of non-malig-
nant neoplasms. The events within this SOC were
reviewed and categorized as malignancies or residual
(i.e., non-malignant) neoplasms. Incidence rates and
between-group differences were computed for individual
and combined events (i.e., all malignancies, all residual
events).
Bone Fracture
Analyses of the adverse event of bone fracture used a
composite endpoint of all identified fractures in the data-
base reported as either specific adverse events or results
of a radiologic evaluation, or those described within a
narrative of a serious adverse event. The primary analysis
was performed excluding data following initiation of gly-
cemic rescue therapy to avoid the potentially confound-
ing influence of glycemic rescue therapy, since
pioglitazone was used as rescue therapy in a number of
studies. To improve sensitivity, the primary analysis also
excluded face or skull fractures and those related to high-Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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impact trauma (e.g., motor vehicle accident or fall from
greater than 5 feet). An additional analysis evaluated the
composite endpoint of all bone fractures regardless of
location or association with high-impact trauma. To con-
trol for the confounding effects of initiating treatment
with a thiazolidinedione as part of blinded study therapy,
a separate pooled analysis was performed that excluded
data from studies and portions of studies in which a thi-
azolidinedione (i.e., pioglitazone or rosiglitazone) was
initiated as part of blinded study therapy in any treatment
group.
Infection
Due to theoretical concerns regarding the potential role
of DPP-4 in immune function, overall and specific
adverse events of infection were examined to identify
potential infections or trends suggestive of compromised
immunity.
Angioedema
Angioedema events and angioedema-related events,
based upon an expanded version of the Standard Med-
DRA Query (SMQ) that included anaphylactic reactions
and hypersensitivity (Appendix II), were summarized by
treatment group for the periods with and without expo-
sure to an angiotensin-converting enzyme (ACE) inhibi-
tor. Exposure to an ACE inhibitor was defined as the total
days of use of an ACE inhibitor during the double-blind
treatment period, with patients contributing to patient-
years of exposure to an ACE inhibitor for the actual
period of time that they were reported to have been tak-
ing an ACE inhibitor and to patient-years of non-expo-
sure for the actual period of time that they were reported
not to have been taking an ACE inhibitor.
Liver Function Tests
Percentages of patients meeting predefined limits of
change (PDLC) for alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) were compared
between groups using the previously described statistical
analysis.
Results
Patient Characteristics and Exposure
In this pooled analysis, there were 10,246 patients overall,
with 5,429 in the sitagliptin group and 4,817 in the non-
exposed group. At baseline, patients in the total cohort
had an average age of 55 years (range: 19 to 91 years; 18%
≥ 65 years), a median duration of diabetes of 3.5 years,
and a mean HbA1c of 8.4%. Men comprised 54% of this
cohort. The participating population was 64% White,
15% Asian, and 6% Black. The per study contribution
from Hispanic patients varied from 0% to 36% depending
on the method of data capture (see Methods) as well as
the study population. At baseline, 11% of patients had a
history of cardiovascular disease, and 82% had additional
cardiovascular risk factors besides type 2 diabetes and
cardiovascular disease, including hypertension (55%),
history of dyslipidemia/hypercholesterolemia (50%), and
history of smoking (40%). There were no meaningful dif-
ferences between treatment groups in these baseline
characteristics or in the frequency or type of baseline
medical conditions or other medications used.
The mean exposure to study drug and total patient-
years in study were greater in the sitagliptin group rela-
tive to the non-exposed group: 282 dosing days (range = 1
to 791) relative to 259 dosing days (1 to 801), respectively.
The cumulative patient exposure was 4,709 patient-years
for the sitagliptin group and 3,943 patient-years for the
non-exposed group. In the sitagliptin group, 1,805
patients were treated for at least 1 year, with 584 of these
patients treated for 2 years; the corresponding numbers
of patients were 1,320 and 470 in the non-exposed group.
In this pooled analysis of studies 12 weeks to 2 years in
duration, the proportions of patients discontinuing treat-
ment were 33% in the sitagliptin group and 35% in the
non-exposed group, with generally similar reasons for
discontinuations in the two treatment groups (Table 2).
Safety and Tolerability
Summary measures of reported adverse events and
deaths were similar in the sitagliptin and non-exposed
groups, except that the incidence rate of drug-related
adverse events was higher in the non-exposed group
(Table 3), primarily due to the greater incidence rate of
adverse events of hypoglycemia reported for the non-
exposed group. Incidence rates for each SOC are in Table
4. There were 3 SOCs (Blood and Lymphatic System Dis-
orders, Skin and Subcutaneous Disorders, and Metabo-
lism and Nutrition Disorders) for which the 95% CI for
the between-group difference in incidence rate excluded
0. The between-group difference in incidence rate of
pooled adverse events in the Blood and Lymphatic Sys-
tem Disorders SOC was primarily due to slightly higher
incidence rates of the specific adverse events of anemia
and iron-deficiency anemia in the sitagliptin group. For
the specific adverse event of anemia, the incidence rates
were 0.4 and 0.2 per 100 patient-years in the sitagliptin
and non-exposed groups, respectively, with a between-
group difference (95% CI) of 0.2 (-0.1, 0.4); for iron-defi-
ciency anemia, the incidence rates were 0.3 and 0.1, with
a between-group difference (95% CI) of 0.2 (-0.0, 0.4). For
the Skin and Subcutaneous Disorders SOC, the adverse
events of contact dermatitis (0.7 vs. 0.3), macular rash
(0.3 vs. 0.1), and acne (0.2 vs. 0.0) accounted for the
higher incidence rate in the sitagliptin group relative to
the non-exposed group, respectively. The between-group
difference in the incidence rate of pooled adverse events
in the Metabolism and Nutrition Disorders SOC was pri-
marily due to a higher incidence rate of hypoglycemia in
the non-exposed group (discussed below).Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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The incidence rates of specific adverse events with at
least 1 incident event per 100 patient-years in either
group are listed in Table 5. The most commonly reported
adverse events (i.e., ≥ 5 incident events per 100 patient-
years in either group) were hypoglycemia, upper respira-
tory tract infection, diarrhea, nasopharyngitis, influenza,
and headache. Of these events, nasopharyngitis and
headache occurred more frequently in the sitagliptin
group, although the 95% CI around the between-group
differences included 0. Hypoglycemia, diarrhea, upper
respiratory infection, and influenza occurred more fre-
quently in the non-exposed group, with the 95% CIs
around the between-group differences excluding 0 for
hypoglycemia and diarrhea.
For specific adverse events reported in which the
between-group difference in incidence rates was >0.2
incident events per 100 patient-years and for which the
95% CI around the between-group difference excluded 0,
there were 5 specific adverse events reported at a higher
incidence rate in the sitagliptin group and 7 reported at a
higher incidence rate in the non-exposed group (Table 6).
The largest between-group differences in incidence rates
were observed for the adverse events of hypoglycemia
(6.8) and diarrhea (2.3), which occurred with higher inci-
dence rates in the non-exposed group, and for constipa-
tion (0.8), which occurred with a higher incidence rate in
the sitagliptin group (discussed below). While the inci-
dence rate of "protein urine present" was also higher in
the sitagliptin group, when the adverse events of albu-
minuria, microalbuminuria, albumin urine present, pro-
tein urine present, and proteinuria were combined and
assessed, the between-group difference (95% CI) was 0.1
per 100 patient-years (-0.2, 0.5). Additional analyses of
renal safety included assessment of mean changes in
serum creatinine over time as well as the proportions of
patients whose serum creatinine met the PDLC criterion
of 2 or more consecutive measurements with an increase
from baseline of ≥ 0.3 mg/dL or of ≥ 50% (modified from
Mehta et al [22]); results of these analyses showed no sig-
nificant between-group differences.
The incidence rate of drug-related adverse events over-
all was higher in the non-exposed group compared with
the sitagliptin group (Table 3), primarily due to a greater
proportion of patients reported with hypoglycemia in the
non-exposed group. Analyses of drug-related adverse
events that occurred at an incidence rate of at least 0.2
incident events per 100 patient-years in either treatment
group are in Table 7. In addition to hypoglycemia, the
incidence rates of drug-related adverse events of abdomi-
nal pain, diarrhea, gastritis, weight increased, and paraes-
thesia were higher in the non-exposed group compared
to the sitagliptin group, with the 95% CI around the
between-group differences excluding 0 (Table 7). Consti-
pation (discussed below) was the only drug-related
adverse event with a higher incidence rate in the sitaglip-
tin group (0.8) than in the non-exposed group (0.5), with
the 95% CI around the between-group differences exclud-
ing 0.
The incidence rates of serious adverse events overall
were similar in each treatment group (Table 3). Specific
serious adverse events, irrespective of the relationship to
study drug, that were reported with an incidence rate of
at least 0.2 incident events per 100 patient-years in either
treatment group are in Table 8. For myocardial ischemia,
Table 2: Overall disposition
Sitagliptin
100 mg
Non-exposed
RANDOMIZED, N 5429 4817
n (%) n (%)
DISCONTINUED 1818 (33.5) 1694 (35.2)
Reason for discontinuation
Adverse event 239 (4.4) 216 (4.5)
Lack of efficacy* 614 (11.3) 520 (10.8)
Lost to follow-up 222 (4.1) 180 (3.7)
Protocol violation 98 (1.8) 99 (2.1)
Protocol-specific criteria 61 (1.1) 55 (1.1)
Withdrawal of consent 336 (6.2) 367 (7.6)
Other reasons† 248 (4.6) 257 (5.3)
* Includes patients not meeting the protocol-specified, progressively stricter glycemic rescue criteria and/or not meeting the investigator's 
expectations of glycemic improvement.
† Includes pregnancy, physician decision, patient moved, site terminated, and other.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
http://www.biomedcentral.com/1472-6823/10/7
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the 95% CI for the between-group difference in incidence
rates excluded 0, favoring the sitagliptin group. There
were no other notable between-group differences.
Adverse Events of Interest
Hypoglycemia
The incidence rates of hypoglycemia were based upon
symptomatic reports of hypoglycemia, regardless of a
concurrent glucose measurement, although a majority
(73.9%) of events (including incident events and subse-
quent events) was confirmed by a (fingerstick) glucose of
≤ 70 mg/dL. The predefined primary analysis for hypo-
glycemia (i.e., excluding data after initiation of glycemic
rescue therapy) showed a between-group difference (95%
CI) of -6.7 incident events per 100 patient-years (-8.2,
-5.3), favoring the sitagliptin group (Table 9). The differ-
ence observed for hypoglycemia was mainly due to the
use of a sulfonylurea as a comparator agent in 2 studies of
up to 2 years in duration [11,23,24], as well as a study in
which patients were switched from placebo to a sulfony-
lurea during a double-blind continuation period (P020 in
Table 1). However, results from some individual studies
included in this pooled analysis (in which sitagliptin was
added to either a sulfonylurea with or without metformin
[25] or to insulin with or without metformin [26]) dem-
onstrated an increased risk for hypoglycemia with sita-
gliptin relative to placebo. Therefore, a separate pooled
analysis of hypoglycemia was conducted in which con-
founding effects of a sulfonylurea or insulin as either
background or comparator therapy were removed. In this
analysis, which compares sitagliptin to either placebo or
AHAs not known to increase rates of hypoglycemia (i.e.,
metformin or a thiazolidinedione), the incident rates of
hypoglycemia were 3.1 and 3.3 per 100 patient-years in
the sitagliptin (n = 4175) and non-exposed (n = 3572)
groups, respectively.
Gastrointestinal Symptoms
The predefined primary analysis (i.e., excluding data after
initiation of glycemic rescue therapy) of select GI adverse
events demonstrated lower incidence rates for the pooled
select terms and for the specific adverse event of diarrhea
in the sitagliptin group (Table 9). The differences
observed for diarrhea mainly reflected the use of met-
formin as a comparator; when the confounding effects of
initiation of metformin were removed, the incidence rates
were 4.9 and 5.0 per 100 patient-years in the sitagliptin (n
= 3904) and non-exposed (n = 3310) groups, respectively.
There were no meaningful differences between treatment
Table 3: Adverse event summary
Incidence Rate per 100 Patient-years†
Sitagliptin 100 mg Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
With one or more adverse 
events
153.5 162.6 -7.6 (-15.6, 0.3)
With drug-related‡ adverse 
events
20.0 26.8 -6.4 (-8.7, -4.1)
With serious adverse events 7.8 7.9 -0.1 (-1.3, 1.1)
With serious drug-related‡ 
adverse events
0.4 0.3 0.1 (-0.1, 0.4)
Who died 0.3 0.5 -0.2 (-0.5, 0.1)
Discontinued due to adverse 
events
4.8 5.2 -0.5 (-1.5, 0.4)
Discontinued due to drug-
related‡ adverse events
1.7 2.3 -0.5 (-1.1, 0.1)
Discontinued due to serious 
adverse events
1.7 1.7 -0.0 (-0.6, 0.5)
Discontinued due to serious 
drug-related‡ adverse events
0.2 0.1 0.1 (-0.1, 0.3)
CI = confidence interval
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡As determined by the investigator.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
http://www.biomedcentral.com/1472-6823/10/7
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Table 4: Summary of adverse events by system organ class
Incidence Rate per 100 Patient-years†
System Organ Class Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Blood and Lymphatic System 
Disorders
1.1 0.6 0.4 (0.0, 0.8)
Cardiac Disorders 4.2 4.3 -0.2 (-1.1, 0.7)
Congenital, Familial, and 
Genetic Disorders
0.2 0.3 -0.0 (-0.3, 0.2)
Ear And Labyrinth Disorders 1.7 2.0 -0.4 (-1.0, 0.2)
Endocrine Disorders 0.3 0.5 -0.2 (-0.5, 0.1)
Eye Disorders 4.0 4.3 -0.2 (-1.1, 0.6)
Gastrointestinal Disorders 26.0 27.7 -1.2 (-3.7, 1.2)
General Disorders And 
Administration Site 
Conditions
8.8 9.3 -0.6 (-1.9, 0.8)
Hepatobiliary Disorders 1.3 1.1 0.2 (-0.3, 0.7)
Immune System Disorders 1.0 1.1 -0.1 (-0.6, 0.3)
Infections And Infestations 49.2 48.1 1.8 (-1.7, 5.3)
Injury, Poisoning And 
Procedural Complications
9.7 9.4 0.7 (-0.7, 2.1)
Investigations 15.1 15.7 -1.2 (-3.0, 0.6)
Metabolism And Nutrition 
Disorders
9.3 16.3 -6.8 (-8.5, -5.2)
Musculoskeletal And 
Connective Tissue Disorders
20.3 19.4 1.0 (-1.1, 3.0)
Neoplasms Benign, Malignant 
And Unspecified
2.2 1.7 0.6 (-0.0, 1.2)
Nervous System Disorders 15.4 15.5 -0.2 (-2.0, 1.6)
Pregnancy, Puerperium, and 
Perinatal Conditions
0.0 0.1 -0.0**
Psychiatric Disorders 4.6 4.7 0.0 (-0.9, 1.0)
Renal And Urinary Disorders 3.0 3.0 -0.1 (-0.8, 0.7)
Reproductive System And 
Breast Disorders
2.8 3.2 -0.3 (-1.1, 0.5)
Respiratory, Thoracic And 
Mediastinal Disorders
8.8 8.6 0.2 (-1.2, 1.4)
Skin And Subcutaneous Tissue 
Disorders
8.6 7.3 1.3 (0.1, 2.5)
Social Circumstances 0.0 0.1 -0.0**
Surgical and Medical 
Procedures
0.1 0.1 0.0**
Vascular Disorders 5.8 5.8 -0.2 (-1.2, 0.9)
CI = confidence interval
† 100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
** 95% CIs were not computed for events that occurred in fewer than 4 patients in both groups, because the CIs would necessarily have 
included 0.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
http://www.biomedcentral.com/1472-6823/10/7
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groups in the incidence rates for the specific events of
nausea or vomiting, or the composite abdominal pain
events (Table 9). The incidence rate of the adverse event
of constipation was higher in the sitagliptin group (2.6)
than in the non-exposed group (1.9) (Table 6); the major-
ity of events were mild in intensity, with 1 patient in each
treatment group discontinuing treatment due to the
adverse event.
Cardiovascular
The incidence rates of adverse events in the Cardiac Dis-
orders SOC were similar between groups (Table 4). In a
prespecified MACE analysis (see Appendix I for listing of
MACE terms included in the analysis), there was a total
of 64 patients for whom at least 1 MACE-related adverse
event was reported. The incidence rates were 0.6 per 100
patient-years in the sitagliptin group and 0.9 in the non-
exposed group, for a between-group difference (95% CI)
of -0.3 (-0.7, 0.1). In the prespecified analysis, the risk
ratio for sitagliptin-exposed relative to non-exposed
patients was 0.68 (95% CI: 0.41, 1.12). In a sensitivity
analysis using the Mantel-Haenszel approach, the results
were consistent (risk ratio [95% CI] = 0.67 [0.39, 1.13]).
Malignancy
The incidence rates of adverse events in the Neoplasms
SOC overall were 2.2 per 100 patient-years in the sitaglip-
tin-exposed group and 1.7 in the non-exposed group
(between-group difference [95% CI] of 0.6 [-0.0, 1.2]).
The analysis of the combined events of malignancies
within the Neoplasms SOC showed an incidence rate of
1.0 for both the sitagliptin and non-exposed groups
(Table 10). Low incidence rates of a wide range of specific
malignancies were reported with similar frequencies in
both treatment groups. The most frequently reported
events were basal cell carcinoma (0.2 per 100 patient-
years in each group, with a between-group difference
[95% CI] of 0.0 [-0.2, 0.2]), breast cancer (in women, 0.3
and 0.2 in the sitagliptin and non-exposed groups,
respectively, with a between-group difference [95% CI] of
0.1 [-0.2, 0.5]) and prostate cancer (in men, 0.2 in each
group, with a between-group difference [95% CI] of -0.0
[-0.3, 0.3]) (Table 8). Results from a sensitivity analysis
excluding events of non-melanomatous skin cancers
showed similar between-group incidence rates: 0.8 in
each group, with a between-group difference (95% CI) of
-0.1 (-0.5, 0.3).
After excluding malignancies, a higher incidence rate
for the combined residual terms of non-malignant
adverse events within the Neoplasms SOC was observed
in the sitagliptin group compared with the non-exposed
group (between-group difference [95% CI] of 0.6 [0.2,
1.1]; Additional file 1: Supplemental Table S1). This dif-
ference was not the result of an imbalance in any single
adverse event or any group of biologically-related adverse
events. Among these residual adverse events, the most
frequently reported were uterine leiomyoma/leiomyoma
(in women, 0.5 and 0.2 in the sitagliptin and the non-
exposed groups, respectively; between group difference
[95% CI] of 0.4 [-0.0, 0.9]) and lipoma (0.2 and 0.1 in the
sitagliptin and the non-exposed groups, respectively;
between-group difference [95% CI] of 0.1 [-0.0, 0.3]).
Among adverse event terms within the Neoplasms SOC,
uterine leiomyoma was the most common condition
reported as part of patient medical history (i.e., present
prior to randomization) in 3.0% and 2.8% of randomized
women in the sitagliptin and non-exposed groups,
respectively, while lipoma was reported as part of medical
history in 0.3% and 0.4% of randomized patients in the
sitagliptin and non-exposed groups, respectively.
To further explore the small between-group difference
in the incidence rate for the residual, non-malignant
adverse events overall within the Neoplasms SOC, analy-
ses were conducted in the following additional popula-
tions: (1) a broader patient population (N = 6748 and
4855 patients in the sitagliptin and non-exposed groups,
respectively) consisting of the primary population plus
patients dosed with sitagliptin other than 100 mg daily
(i.e., 12.5, 50, and 200 mg daily) or comparator, including
patients with renal insufficiency who were randomized to
receive dose-adjusted sitagliptin or comparator, and (2)
the subset of this broader patient population randomized
to receive the higher dose of sitagliptin (200 mg once
daily; N = 456) or comparator (N = 363) for up to 1 year.
These analyses showed results similar to those observed
in the primary analysis, with between-group differences
(95% CI) in the overall incidence rate for the residual
non-malignant adverse events within the Neoplasms
SOC of 0.7 (0.3, 1.2) and 0.6 (-2.6, 3.4) for the broader
population and the sitagliptin 200-mg population,
respectively. Additional analyses of residual non-malig-
nant adverse events within the Neoplasms SOC com-
bined with neoplasms that MedDRA assigns to other
SOCs (e.g., polyps) were consistent with findings limited
to analysis of the residual non-malignant adverse events
within the Neoplasms SOC.
Bone Fracture
In the primary analysis of bone fracture, which excluded
fractures of the face and skull and those related to high-
impact trauma, the incidence rates of bone fractures were
0.8 per 100 patient-years in the sitagliptin group and 1.0
in the non-exposed group (between-group difference
[95% CI] = -0.1 [-0.6, 0.3]). Results were similar to the
above when the potentially confounding influence of ini-
tiation of a thiazolidinedione was eliminated. The inci-
dence rate of overall bone fractures, including fractures of
the face and skull and those related to high-impact
trauma, was 1.1 in each treatment group (between-group
difference [95% CI] = 0.1 [-0.4, 0.5]).Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
http://www.biomedcentral.com/1472-6823/10/7
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Table 5: Adverse events with at least 1 incident event per 100 patient-years in one or both groups
Adverse Event Incidence Rate per 100 Patient-years†
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Gastrointestinal disorders SOC
Abdominal pain‡^ 1.3 1.7 -0.5 (-1.0, 0.0)
Constipation 2.6 1.9 0.8 (0.1, 1.4)
Diarrhea‡ 6.9 9.6 -2.3 (-3.6, -1.0)
Dyspepsia 2.0 1.6 0.4 (-0.1, 1.0)
Gastritis 1.2 1.5 -0.3 (-0.8, 0.2)
Gastroesophageal reflux 
disease
1.1 0.8 0.3 (-0.1, 0.8)
Nausea‡ 3.0 3.8 -0.5 (-1.3, 0.3)
Toothache 1.2 1.3 -0.2 (-0.7, 0.3)
Vomiting‡ 1.8 1.9 0.0 (-0.6, 0.6)
General disorders and administration site conditions SOC
Fatigue 1.8 2.5 -0.6 (-1.3, -0.0)
Peripheral Edema 2.4 2.4 -0.0 (-0.7, 0.6)
Infections and infestations SOC
Bronchitis 4.2 3.8 0.4 (-0.4, 1.3)
Cellulitis 0.8 1.0 -0.2 (-0.6, 0.2)
Gastroenteritis 2.0 1.9 0.1 (-0.5, 0.7)
Gastroenteritis Viral 1.0 1.0 0.0 (-0.4, 0.5)
Influenza 4.5 5.2 -0.7 (-1.7, 0.2)
Nasopharyngitis 7.7 7.0 0.9 (-0.3, 2.1)
Pharyngitis 1.5 1.4 0.1 (-0.4, 0.6)
Sinusitis 2.7 2.7 0.1 (-0.6, 0.8)
Upper respiratory tract 
infection
8.6 9.0 -0.3 (-1.6, 1.0)
Urinary tract infection 4.1 4.2 -0.2 (-1.1, 0.6)
Viral infection 1.1 0.9 0.2 (-0.2, 0.7)
Injury, poisoning, and procedural complications SOC
Contusion 1.0 0.8 0.1 (-0.3, 0.5)
Muscle strain 0.9 1.0 -0.1 (-0.6, 0.3)
Investigations SOC
ALT increased 1.5 1.4 0.1 (-0.4, 0.6)
AST increased 1.0 1.0 0.0 (-0.4, 0.4)
Blood glucose decreased 0.5 1.0 -0.5 (-0.9, -0.1)
Blood glucose increased 2.3 3.6 -1.3 (-2.1, -0.6)
Blood uric acid increased 1.0 0.8 0.2 (-0.2, 0.6)
Weight increased 0.8 1.0 -0.2 (-0.7, 0.2)
Metabolism and nutrition disorders SOC
Hyperglycemia 1.2 1.4 -0.2 (-0.7, 0.3)
Hypoglycemia‡ 5.2 12.1 -6.8 (-8.3, -5.5)Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
http://www.biomedcentral.com/1472-6823/10/7
Page 12 of 21
Infection
The incidence rates for infections overall and for specific
adverse events of infection were generally similar
between groups (Tables 4 and 5). A sensitivity analysis
that included all patients with events of upper respiratory
tract infection or related terms (including viral upper
respiratory tract infection, upper respiratory tract infec-
tion bacterial, and upper respiratory fungal infection)
demonstrated no meaningful between-group difference
(-0.5 per 100 patient-years [95% CI: -1.9, 0.8]). A similar
sensitivity analysis conducted for the adverse event of
bronchitis (including all patients with events in the Infec-
tions and Infestations SOC that contained the term
"bronchitis") also showed no meaningful between-group
difference (0.5 [95% CI: -0.4, 1.4]). The incidence rate of
the generally more severe, respiratory-specific adverse
event of pneumonia was similar in both treatment groups
(0.8 in each treatment group; between-group difference
[95% CI] = 0.1 [-0.3, 0.5]).
For the adverse event of urinary tract infection, the
incidence rates were balanced between the sitagliptin and
the non-exposed groups (Table 5). Similar incidence rates
for both groups were also observed when infection events
of cystitis were pooled with combined events of urinary
tract infection (including urinary tract infection, Escheri-
chia urinary tract infection, and urinary tract infection,
bacterial): 4.5 and 4.8 per 100 patient-years in the sita-
gliptin and the non-exposed groups, respectively, with a
between-group difference of -0.3 (95% CI: -1.3, 0.6). Inci-
dence rates of the generally more severe infection of
Musculoskeletal and connective tissue disorders SOC
Arthralgia 3.4 3.7 -0.3 (-1.2, 0.5)
Back pain 4.3 4.1 0.1 (-0.8, 1.0)
Muscle spasms 1.2 1.5 -0.3 (-0.8, 0.2)
Musculoskeletal pain 1.6 1.6 -0.1 (-0.6, 0.5)
Myalgia 1.2 1.2 -0.0 (-0.5, 0.4)
Neck pain 0.7 1.0 -0.3 (-0.7, 0.1)
Osteoarthritis 1.6 1.1 0.5 (-0.0, 1.0)
Pain in extremity 2.8 2.1 0.7 (0.1, 1.4)
Nervous system disorders SOC
Dizziness 2.8 2.7 0.1 (-0.6, 0.9)
Headache 5.8 5.6 0.4 (-0.7, 1.4)
Hypoesthesia 0.7 1.1 -0.4 (-0.8, 0.0)
Paraesthesia 1.0 1.2 -0.2 (-0.7, 0.3)
Psychiatric disorders SOC
Anxiety 0.9 1.0 -0.1 (-0.5, 0.3)
Depression 1.4 1.2 0.3 (-0.2, 0.8)
Insomnia 1.5 1.4 0.0 (-0.5, 0.6)
Respiratory, thoracic, and mediastinal disorders SOC
Cough 2.7 2.6 0.0 (-0.7, 0.7)
Oropharyngeal pain 1.3 1.2 0.1 (-0.4, 0.6)
Skin and subcutaneous tissue disorders SOC
Rash 1.3 0.9 0.4 (-0.1, 0.8)
Vascular disorders SOC
Hypertension 3.6 3.6 -0.1 (-1.0, 0.7)
CI = confidence interval;
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡For these events, see also Table 9 for the results of the predefined primary analysis which excludes data after initiation of glycemic rescue 
therapy.
^Abdominal pain includes abdominal pain, upper and lower abdominal pain, and abdominal and epigastric discomfort.
Table 5: Adverse events with at least 1 incident event per 100 patient-years in one or both groups (Continued)Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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pyelonephritis (including pyelonephritis, pyelonephritis
acute, and pyelonephritis chronic) were generally similar
between the two treatment groups: 0.1 and 0.2 in the sita-
gliptin and non-exposed groups, respectively, with a
between-group difference of -0.1 (95% CI: -0.3, 0.1).
The incidences of other events potentially suggestive of
an immunodeficiency, due to either severity or due to the
specific nature of the infection, were also examined.
There was a lower incidence rate of the adverse event of
sepsis/Staphylococcal sepsis (all reported as serious) in
the sitagliptin group (1 patient, 0.0 per 100 patient-years)
relative to the non-exposed group (4 patients, 0.1). The
overall incidence rates of adverse experiences of
abscesses (including any term containing abscess) were
similar for the sitagliptin group (1.2) relative to the non-
exposed group (1.3), with a between-group difference of
-0.1 (95% CI: -0.6, 0.4). The incidence rates for combined
events of herpes infections (including genital herpes, her-
pes ophthalmic, herpes simplex, herpes viral infection,
herpes zoster, and oral herpes) were similar in the sita-
gliptin group (0.8) and the non-exposed group (0.9), with
a between-group difference of -0.0 (95% CI: -0.4, 0.4).
There was no increase in recrudescence of infection (i.e.,
herpes zoster), with incidence rates of 0.5 and 0.6 in the
sitagliptin and non-exposed groups, respectively
(between-group difference of -0.1 [95% CI: -0.4, 0.2]). For
all these events, patients treated with sitagliptin generally
had no greater frequency, severity, or duration of events
relative to patients not treated with sitagliptin. There was
no signal for an increased risk of opportunistic infections
in patients treated with sitagliptin.
Angioedema
A t  b a s e l i n e ,  3 1 %  o f  p a t i e n t s  r e p o r t e d  t a k i n g  a n  A C E
inhibitor, and approximately 34% were on an ACE inhibi-
tor at any time during the clinical studies (for a total
exposure of 1,532 and 1,251 patient-years on an ACE
Table 6: Adverse events for which the 95% CI around the difference in incidence rates excludes 0 and the between-group 
difference is >0.2 incident events per 100 patient-years
Adverse Event Incidence Rate per 100 Patient-years†
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Sitagliptin > Non-exposed
Atrial fibrillation‡ 0.4 0.2 0.3 (0.0, 0.6)
Constipation 2.6 1.9 0.8 (0.1, 1.4)
Protein urine present^ 0.5 0.2 0.3 (0.0, 0.5)
Pain in extremity 2.8 2.1 0.7 (0.1, 1.4)
Dermatitis Contact 0.7 0.3 0.5 (0.1, 0.8)
Non-exposed > Sitagliptin
Diarrhea# 6.9 9.6 -2.3 (-3.6, -1.0)
Fatigue 1.8 2.5 -0.6 (-1.3, -0.0)
Blood glucose decreased 0.5 1.0 -0.5 (-0.9, -0.1)
Blood glucose increased 2.3 3.6 -1.3 (-2.1, -0.6)
Blood triglycerides increased 0.5 0.8 -0.4 (-0.7, -0.0)
Hypoglycemia# 5.2 12.1 -6.8 (-8.3, -5.5)
Sinus headache 0.1 0.3 -0.3 (-0.5, -0.1)
CI = confidence interval
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡When atrial fibrillation and atrial flutter were combined, the between-group difference (95% CI) was 0.2 (-0.1, 0.5). Incidence rates for atrial 
flutter were 0.0 and 0.1 for the sitagliptin and the non-exposed groups, respectively, with a between-group difference [95% CI] of -0.1 (-0.3, 
-0.0).
^When albuminuria, microalbuminuria, albumin in urine present, protein urine present, and proteinuria were combined, the between-group 
difference (95% CI) was 0.1 (-0.2, 0.5).
# For these events, see also Table 9 for the results of the predefined primary analysis which excludes data after initiation of glycemic rescue 
therapy.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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Table 7: Adverse events considered to be related to study drug‡ that occurred at an incidence rate of ≥ 0.2 incident events 
per 100 patient-years in one or both groups
Adverse Event Incidence Rate per 100 Patient-years†
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Gastrointestinal disorders SOC
Abdominal discomfort 0.3 0.3 0.0 (-0.3, 0.3)
Abdominal distension 0.3 0.2 0.1 (-0.1, 0.3)
Abdominal pain 0.1 0.5 -0.5 (-0.8, -0.2)
Abdominal pain upper 0.5 0.8 -0.2 (-0.6, 0.1)
Constipation 0.8 0.5 0.4 (0.1, 0.8)
Diarrhea 2.4 4.5 -1.8 (-2.7, -1.0)
Dry mouth 0.1 0.3 -0.1 (-0.4, 0.1)
Dyspepsia 0.5 0.5 0.0 (-0.3, 0.3)
Flatulence 0.3 0.5 -0.1 (-0.4, 0.2)
Gastritis 0.1 0.5 -0.3 (-0.6, -0.1)
Gastroesophageal reflux 
disease
0.2 0.1 0.1 (-0.1, 0.3)
Nausea 1.3 1.8 -0.4 (-1.0, 0.1)
Vomiting 0.4 0.4 -0.0 (-0.3, 0.3)
General disorders and administration site conditions SOC
Fatigue 0.6 0.7 -0.2 (-0.6, 0.2)
Peripheral Edema 0.4 0.6 -0.2 (-0.5, 0.1)
Infections and infestations SOC
Upper respiratory tract 
infection
0.4 0.3 0.2 (-0.1, 0.5)
Urinary tract infection 0.3 0.1 0.1 (-0.1, 0.3)
Investigations SOC
ALT increased 0.5 0.4 0.0 (-0.3, 0.3)
AST increased 0.3 0.4 -0.2 (-0.5, 0.1)
Blood creatine phosphokinase 
increased
0.2 0.1 0.1 (-0.0, 0.3)
Blood glucose decreased 0.3 0.5 -0.2 (-0.5, 0.0)
Blood glucose increased 0.3 0.5 -0.2 (-0.5, 0.1)
Blood uric acid increased 0.3 0.2 0.1 (-0.2, 0.3)
Creatinine renal clearance 
decreased
0.3 0.3 0.0 (-0.2, 0.2)
Glycosylated hemoglobin 
increased
0.1 0.2 -0.1 (-0.3, 0.1)
Weight decreased 0.2 0.1 0.1 (-0.1, 0.3)
Weight increased 0.2 0.5 -0.3 (-0.6, -0.0)
Metabolism and nutrition disorders SOC
Decreased appetite 0.2 0.2 0.1 (-0.1, 0.3)
Hyperglycemia 0.1 0.2 -0.1 (-0.4, 0.0)
Hypoglycemia 3.5 7.5 -3.8 (-5.0, -2.8)Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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inhibitor for the sitagliptin and non-exposed groups,
respectively). In this analysis, 90 incident angioedema-
related events were reported, of which 31 occurred in
patients while on an ACE inhibitor. The incidence rates of
angioedema-related events while on an ACE inhibitor
were similar in the sitagliptin and non-exposed groups
(1.0 and 1.3 per 100 patient-years, respectively). The inci-
dence rate while not on an ACE inhibitor was 1.1 in each
group. For the specific adverse event of angioedema, the
incidence rates were 0.06 and 0.08 while on an ACE
inhibitor and 0.03 and 0.04 while not on an ACE inhibitor
in the sitagliptin and non-exposed groups, respectively.
Skin
As described earlier, a few adverse events accounted for
the modest difference in incidence rates between groups
within the Skin and Subcutaneous Disorders SOC. Of the
adverse events within this SOC, the MedDRA preferred
term of rash was the only skin-related adverse event with
at least 1 incident event per 100 patient-years in either
group (Table 5). No adverse events of Stevens-Johnson
syndrome, 1 event of erythema multiforme (for a patient
in the non-exposed group), and 1 event of leukocytoclas-
tic vasculitis (for a patient in the sitagliptin group) were
reported.
Liver Function Tests
The incidence rates of adverse events of increased ALT or
AST were similar between groups (Table 5). Further, the
proportions of patients in the sitagliptin and non-
exposed groups with their last measurement (obtained
either at time of discontinuation or at the final scheduled
study visit) of ALT ≥ 3 times the upper limit of normal
were 0.8% and 0.7%, respectively, with a between-group
difference (95% CI) of 0.2% (-0.2, 0.5); the proportions
with last AST measurement ≥ 3 times the upper limit of
normal were 0.3% and 0.3%, respectively, with a between-
group difference (95% CI) of -0.0% (-0.3, 0.2).
Discussion
In this updated pooled analysis of 19 double-blind, ran-
domized clinical studies up to 2 years in duration, treat-
ment with the DPP-4 inhibitor, sitagliptin, was generally
well tolerated, with exposure-adjusted incidence rates of
adverse events generally similar to those observed with
other treatments. This updated analysis includes data
from additional treatment regimens and extends the find-
ings of a previously published analysis [1] by including
results from an additional 4,100 patients, thereby increas-
ing the pooled population from 6,139 to 10,246 patients
Musculoskeletal and connective tissue disorders SOC
Arthralgia 0.2 0.2 -0.0 (-0.3, 0.2)
Muscle spasms 0.1 0.2 -0.1 (-0.3, 0.1)
Myalgia 0.1 0.2 -0.1 (-0.3, 0.1)
Nervous system disorders SOC
Dizziness 0.6 0.5 0.1 (-0.2, 0.4)
Headache 1.2 1.1 0.1 (-0.4, 0.6)
Paraesthesia 0.1 0.3 -0.2 (-0.4, -0.0)
Psychiatric disorders SOC
Insomnia 0.2 0.1 0.1 (-0.1, 0.3)
Respiratory, thoracic, and mediastinal disorders SOC
Cough 0.2 0.1 0.0 (-0.2, 0.2)
Skin and subcutaneous tissue disorders SOC
Pruritus 0.2 0.2 -0.0 (-0.3, 0.2)
Rash 0.4 0.2 0.2 (-0.0, 0.5)
Urticaria 0.1 0.2 -0.1 (-0.3, 0.1)
Vascular disorders SOC
Hypertension 0.3 0.2 0.1 (-0.1, 0.3)
CI = confidence interval;
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡As determined by the investigator
Table 7: Adverse events considered to be related to study drug‡ that occurred at an incidence rate of ≥ 0.2 incident events 
per 100 patient-years in one or both groups (Continued)Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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and the total exposure from ~5,300 to ~8,700 patient-
years. Overall, the present findings based on the substan-
tially larger dataset were generally consistent with those
from the previously published pooled analysis of 12 clini-
cal studies.
In the present pooled analysis, the incidence rate of
hypoglycemia was lower in sitagliptin-treated patients
compared to those not treated with sitagliptin. This dif-
ference was mainly due to use of a sulfonylurea as a com-
parator agent in some studies. In clinical trials, the
incidence of hypoglycemia with sitagliptin has been simi-
lar to placebo when sitagliptin is used as monotherapy, as
initial combination therapy with metformin or pioglita-
zone, or as add-on therapy to agents that are not by them-
selves associated with hypoglycemia (e.g., metformin or a
thiazolidinedione) [27-29]. However, when sitagliptin is
added to ongoing therapy with a sulfonylurea or insulin,
there is an increase in the incidence of hypoglycemia
compared with the addition of placebo as might be
expected when an agent that provides additional glycemic
efficacy is used in combination with these agents [25,26].
Thus, the reported incidence rate of hypoglycemia in the
sitagliptin group reflects the combined rate across multi-
ple studies with different treatment regimens. Clinicians
should review the hypoglycemia rates from studies with
specific sitagliptin-based regimens to understand the
potential risks for their patients.
GLP-1 receptor agonists and certain oral AHAs are
associated with an increased risk of specific GI side
effects [4,30]. In the present pooled analysis, the inci-
dences of GI adverse events overall were similar in the
sitagliptin and the non-exposed groups. There was a
small increase in incidence rate (an increase of 0.8 per
100 patient-years) for constipation in sitagliptin-treated
patients and a higher incidence rate of diarrhea in non-
exposed patients. The increase in diarrhea in the non-
exposed group was due to the use of metformin as a com-
parator agent in some trials. The reason for the increased
Table 8: Serious adverse events irrespective of relationship to study drug that occurred at an incidence rate of ≥ 0.2 
incident events per 100 patient-years in one or both groups
Adverse Event Incidence Rate per 100 Patient-years†
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Cardiac disorders SOC
Acute myocardial infarction 0.1 0.2 -0.1 (-0.3, 0.0)
Angina pectoris 0.2 0.1 0.1 (-0.1, 0.3)
Coronary artery disease 0.2 0.4 -0.2 (-0.5, 0.0)
Myocardial infarction 0.2 0.2 0.0 (-0.2, 0.2)
Myocardial ischemia 0.0 0.2 -0.2 (-0.4, -0.1)
General disorders and administration site conditions SOC
Non-cardiac chest pain 0.1 0.3 -0.1 (-0.4, 0.1)
Infections and Infestations SOC
Pneumonia 0.2 0.2 0.1 (-0.2, 0.3)
Neoplasms benign, malignant and unspecified SOC
Basal cell carcinoma 0.2 0.2 0.0 (-0.2, 0.2)
Breast cancer‡ 0.3 0.2 0.1 (-0.2, 0.5)
Prostate cancer‡ 0.2 0.2 -0.0 (-0.3, 0.3)
Nervous system disorders SOC
Cerebrovascular accident 0.1 0.2 -0.1 (-0.3, 0.1)
Transient ischemia attack 0.0 0.2 -0.1 (-0.3, 0.0)
CI = confidence interval
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡ Gender-specific analyses for these adverse events. There were no reports of breast cancer in males.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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incidence of constipation in the sitagliptin group is not
known. While the higher levels of endogenous GLP-1
achieved with DPP-4 inhibitors do not appear to slow
gastric emptying [31,32], increased levels of endogenous
GLP-1 may have some effect on gut motility [33].
Prior meta-analyses of published studies of DPP-4
inhibitors (including sitagliptin and vildagliptin) have
reported an increased risk for infections overall and for
specific infections (nasopharyngitis, upper respiratory
tract infection, and urinary tract infection) [9,26,34]. In
the present analysis, however, no notable between-group
differences in incidence rates were observed for any
infection-related adverse events, including nasopharyngi-
tis, upper respiratory tract infection, and urinary tract
infection. The larger patient population and access to
patient-level data in the present analysis, allowing for a
more-detailed assessment of these adverse events, likely
account for the differences between the present and
aforementioned findings.
An increased risk of bone loss and fracture has been
reported in patients with type 2 diabetes treated with thi-
azolidinediones [6,7]. The present analysis found that
patients treated with sitagliptin had a similar incidence
rate of bone fracture relative to those not exposed to sita-
gliptin. The clinical results with sitagliptin are consistent
with those from a study in an animal model of osteoporo-
sis [35]. In ovariectomized rats, treatment with sitagliptin
had no effect on bone mass relative to vehicle treatment,
whereas treatment with thiazolidinediones exacerbated
bone loss.
Patients with type 2 diabetes are at an increased risk for
cardiovascular morbidity and mortality [36]. This
Table 9: Select gastrointestinal and hypoglycemia adverse events: Predefined primary analysis, which excluded data after 
initiation of glycemic rescue therapy
Adverse Event Incidence Rate per 100 Patient-years†
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Gastrointestinal disorders SOC
One or more select event 
(abdominal pain‡, diarrhea, 
nausea, vomiting)
14.0 17.2 -2.9 (-4.8, -1.1)
Abdominal pain‡ 4.1 4.7 -0.7 (-1.7, 0.3)
Diarrhea 7.1 10.0 -2.5 (-3.9, -1.1)
Nausea 3.1 4.0 -0.7 (-1.6, 0.2)
Vomiting 1.9 1.9 0.0 (-0.6, 0.6)
Metabolism and nutrition disorders SOC
Hypoglycemia 4.9 11.7 -6.7 (-8.2, -5.3)
CI = confidence interval;
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.
‡Abdominal pain includes abdominal pain, upper and lower abdominal pain, and abdominal and epigastric discomfort.
Table 10: Any malignancy adverse events
Adverse Event n/patient-years of exposure (Incidence Rate per 100 Patient-years†)
Sitagliptin
100 mg
Non-exposed Difference between 
Sitagliptin and Non-
exposed (95% CI)*
Any malignancy 46/4690 (1.0) 40/3930 (1.0) -0.0 (-0.5, 0.4)
n = number of patients with ≥ 1 occurrence of the endpoint; CI = confidence interval;
†100 * (number of patients with ≥ 1 event/person years of follow-up time).
* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin 
group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and 
slightly less than zero, respectively.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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increased risk is thought to be related to the high rate of
co-morbidities, such as hypertension and dyslipidemia, as
well as the potential effect of hyperglycemia. However,
interest in the effect of specific antihyperglycemic thera-
pies on cardiovascular outcomes, which was first raised
as a result of the University Group Diabetes Program
[37], has resurfaced subsequent to a meta-analysis that
indicated an increased risk for cardiovascular events with
rosiglitazone [38]. These and other studies have led to an
increased focus on the cardiovascular risk associated
with individual antihyperglycemic agents used to treat
diabetes.
In the present analysis, in which 82% of patients had
cardiovascular risk factors in addition to type 2 diabetes
and cardiovascular disease, there was no difference
between groups in the evaluation of the Cardiac Disor-
ders SOC overall. Further, a MACE analysis focused on
ischemic events revealed that there were 0.6 incident
events per 100 patient-years in the sitagliptin group and
0.9 in the non-exposed group (incidence rate ratio [sita-
gliptin/non-exposed] = 0.68 [95% CI: 0.41, 1.12]). These
results suggest that sitagliptin does not increase cardio-
vascular risk in patients with type 2 diabetes. The impact
of sitagliptin on cardiovascular outcomes when used as
part of usual care will be compared with the impact of
usual care without sitagliptin in the ongoing, random-
ized, placebo-controlled Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS) [39], which is
planned to enroll 14,000 patients age 50 years or older
with type 2 diabetes and documented cardiovascular dis-
ease. The results from this study will provide a compre-
hensive cardiovascular assessment of patients treated
with sitagliptin relative to those not treated with sitaglip-
tin.
Both obesity and diabetes are reported to be associated
with an increased risk of malignancy, potentially related
to the growth-promoting effects of hyperinsulinemia
associated with insulin resistance [40]. In this context, the
impact of antihyperglycemic therapies on the risk of
malignancy has recently been the focus of increasing
attention [3]. In the current pooled dataset, the analysis
of adverse events within the Neoplasms SOC overall,
which includes all adverse event terms for malignant neo-
plasms as well as residual terms for a wide variety of non-
malignant neoplasms, showed a low overall incidence
rate of adverse events in each treatment group. No differ-
ences between groups were observed in the incidence
rate of malignancies overall or in the incidence rates of
any specific malignancy. A slightly higher incidence rate
of adverse events within the Neoplasms SOC overall
observed in the sitagliptin group was due to reports of
different types of non-malignant neoplasms. Of these, the
specific events that were most commonly reported were
lipoma and uterine leiomyoma, consistent with their fre-
quent occurrence in the general adult population [41,42].
Results of additional analyses, including analysis of a
broader patient population and of a population of
patients exposed to the higher 200-mg dose of sitagliptin,
were not suggestive of a dose-dependent relationship to
explain these findings.
Since the residual, non-malignant adverse events in the
Neoplasms SOC included a collection of disparate and
diverse types of lesions of varying histology and biology,
the ability to interpret aggregate data from this type of
categorization may be limited. Thus, while an occult bias
leading to increased ascertainment of events in the sita-
gliptin group can not be ruled out, the large number of
unrelated adverse event terms assessed in these pooled
analyses and the varying and diverse histologies that
underlie the reported neoplasms suggest that the small
increase in the incidence rate of non-malignant neo-
plasms in the sitagliptin group relative to the non-
exposed group may be a stochastic finding and not
related to the use of sitagliptin.
Skin-related adverse events were of interest, since
administration of some DPP-4 inhibitors [43,44], but not
sitagliptin [45], was associated with dose-dependent
necrotic skin lesions in preclinical studies in monkeys
and dogs. However, skin findings consistent with these
preclinical lesions have not been reported in patients in
controlled clinical studies with DPP-4 inhibitors, includ-
ing those contributing to the present pooled analysis for
sitagliptin. In the present analysis, the increased inci-
dence rate of skin-related adverse events overall observed
in the sitagliptin group was due to small differences in a
few adverse events, including contact dermatitis and rash.
Reduced DPP-4 enzyme activity and DPP-4 enzyme
deficiency have been associated with an increase in ACE
inhibitor-induced angioedema in rats and humans
[46,47], and it was hypothesized that concomitant use of
DPP-4 inhibitors and ACE inhibitors could increase the
risk of angioedema-related adverse events. This hypothe-
sis was supported by an analysis of another DPP-4 inhibi-
t o r  [ 8 ] .  H o w e v e r ,  a  h i g h e r  r a t e  o f  a n g i o e d e m a  o r
angioedema-related events was not observed in the pres-
ent analysis in sitagliptin-treated patients compared to
patients not exposed to sitagliptin, regardless of ACE
inhibitor use.
The following are limitations of the present pooled
analysis: the results are from patients included in ran-
domized, controlled clinical studies of up to 2 years in
duration and, thus, may not be fully reflective of use in
the general population; the analysis focused on sitagliptin
100 mg/day, the usual clinical dose; and there were multi-
ple comparisons made without an adjustment for multi-
plicity, which increased the chance for spurious findings.
The strengths of these analyses include: the ability to
account for all reported adverse events using patient-levelWilliams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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data; the large number of clinical trials and patients ana-
lyzed; and the sensitivity analyses supporting the robust-
ness of the findings.
Conclusions
In this updated pooled safety analysis based upon data
available as of July 2009 from over 10,000 patients with
type 2 diabetes, treatment with sitagliptin 100 mg/day
was generally well tolerated as monotherapy, as initial
combination therapy, and as add-on therapy in double-
blind, randomized clinical studies of up to 2 years in
duration. Continued assessment of adverse events
reported from clinical trials and from the post-marketing
environment is ongoing.
Appendix I
The prespecified MedDRA terms for the MACE analysis
Acute myocardial infarction*
Basal ganglia infarction
Basilar artery thrombosis
Brain stem infarction
Brain stem stroke
Brain stem thrombosis
Carotid arterial embolus
Carotid artery thrombosis
Cerebellar artery thrombosis
Cerebellar embolism
Cerebellar infarction*
Cerebral artery embolism
Cerebral artery thrombosis
Cerebral infarction*
Cerebral thrombosis
Cerebrovascular accident*
Coronary artery thrombosis
Coronary bypass thrombosis
Embolic cerebral infarction
Embolic stroke
Hemorrhagic cerebral infarction
Hemorrhagic stroke*
Hemorrhagic transformation stroke
Ischemic cerebral infarction
Ischemic stroke*
Lacunar infarction*
Lateral medullary syndrome
Moyamoya disease
Myocardial infarction*
Papillary muscle infarction
Post procedural myocardial infarction
Post procedural stroke
Silent myocardial infarction*
Stroke in evolution
Thalamic infarction*
Thrombotic cerebral infarction
Thrombotic stroke
Wallenberg syndrome
MACE = major adverse cardiovascular events
Terms marked with an asterisk (*) were observed in the
pooled data set.
Additionally, all deaths determined to be potentially
cardiovascular-related (based on blinded clinical review)
were included in the MACE analysis.
Appendix II
E x p a n d e d  S t a n d a r d  M e d D RA  Q u e ry  ( S M Q )  t e r m s  f o r
angioedema
Allergic edema*
Anaphylactic reaction*,**
Angioedema*
Circumoral edema
Conjunctival edema
Corneal edema
Drug hypersensitivity*,**
Edema mouth
Epiglottic edema
Eye edema
Eye swelling*
Eyelid edema*
Face edema*
Gingival edema
Gingival swelling*
Gleich's syndrome
Hereditary angioedema
Hypersensitivity*,**
Idiopathic urticaria
Laryngeal edema
Laryngotracheal edema
Lip edema
Lip swelling*
Oculorespiratory syndrome
Oropharyngeal swelling
Palatal edema*
Periorbital edema*
Pharyngeal edema
Scleral edema
Small bowel angioedema
Swelling face*
Swollen tongue*
Tongue edema
Tracheal edema
Urticaria*
Urticaria cholinergic
Urticaria chronic
Urticaria popular
*This adverse event was observed in the pooled data
set.
**Additional term included with SMQ.Williams-Herman et al. BMC Endocrine Disorders 2010, 10:7
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